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Phase II Trial of Paclitaxel–Topotecan–Etoposide Followed
by Consolidation Chemoradiotherapy for Limited-Stage
Small Cell Lung Cancer: CALGB 30002
Antonius A. Miller, MD,* Xiaofei F. Wang, PhD,† Jeffrey A. Bogart, MD,‡ Lydia D. Hodgson, MS,†
Caio M. S. Rocha Lima, MD,§ James E. Radford, MD, Everett E. Vokes, MD,¶
and Mark R. Green, MD,§ for the Cancer and Leukemia Group B (CALGB)
Purpose: We sought to evaluate the activity and tolerance of the
rationally designed sequence of paclitaxel–topotecan–etoposide, a
nonplatinum regimen, as induction therapy for limited-stage small-
cell lung cancer before combined chemo- and radiotherapy.
Patients and Methods: Patients with measurable disease, perfor-
mance status 0 to 2, no prior therapy, and adequate organ function
were eligible. Paclitaxel (110 mg/m2, administered intravenously on
day 1), topotecan (1.5 mg/m2, administered orally on days 2 to 4),
and etoposide (160 mg/m2, administered orally on days 5 to 7 every
21 days), with filgrastim for two cycles, were followed by chest
irradiation to 70 Gy (to postinduction tumor volume) concurrent
with carboplatin (area under the curve of 5, administered intrave-
nously on day 1) and etoposide (100 mg/m2 on days 1 to 3 every 21
days) without filgrastim for three cycles (five chemotherapy cycles
total). We aimed to determine the response rates to induction and
overall therapy, overall and failure-free survival, and toxicity. The
primary statistical endpoint was to differentiate between complete
response rates of 50 and 70% for the overall treatment program.
Results: Between June 2001 and January 2003, 65 patients were
enrolled, but one never started therapy, and one was ineligible.
Patient characteristics included male/female, 27/36; white/black/
other/unknown, 58/3/1/1; median age 62 (range, 38–78); perfor-
mance status 0/1/2, 27/33/3. Induction chemotherapy resulted in six
(10%) complete responses and 35 (56%) partial responses. Overall
response to chemoradiotherapy included 27 (43%; 95% confidence
interval [CI] 30–56%) complete responses and 24 (38%) partial
responses. Median progression-free survival is 12 months (95% CI,
9–15 months). Median overall survival is 20 months (95% CI,
16–24 months). Frequent (20%) grade 3/4 toxicities during all
therapy included neutropenia, febrile neutropenia, anemia, throm-
bocytopenia, fatigue, and dysphagia. One patient died of febrile
neutropenia, one died of febrile neutropenia and typhlitis, and one
patient who declined transfusion for anemia died of cardiac isch-
emia.
Conclusions: This treatment regimen has significant activity in
limited-stage small-cell lung cancer but did not meet our prospec-
tively defined criteria for further investigation in this setting. The
addition of etoposide and the use of a sequenced administration
schedule did not seem to improve overall activity beyond our prior
experience with a topotecan–paclitaxel doublet.
Key Words: Phase II, Paclitaxel, Topotecan, Etoposide, Small-cell
lung cancer.
(J Thorac Oncol. 2007;2: 645–651)
Lung cancer is the leading cause of cancer deaths in bothmales and females in the United States.1 A recent analysis
indicates that the proportion of small-cell lung cancer (SCLC)
among all lung cancer histologic types decreased from 17%
in 1986 to 13% in 2002.2 Only modest improvements in
survival have been accomplished in the last 30 years.2 De-
spite the activity and demonstrated survival benefit of che-
motherapy, the majority of patients still die of this disease,
even if it is considered limited stage at the time of diagnosis.
Therefore, further therapeutic advances are needed. Pacli-
taxel, topotecan, and etoposide all have activity in SCLC.
Etoposide has long been noted for its schedule-dependent
activity in SCLC, with several days of exposure being supe-
rior to single-day therapy.3 Single-agent topotecan has similar
activity to the combination of cyclophosphamide, doxorubi-
cin, and vincristine for the treatment of recurrent SCLC.4
Paclitaxel targets microtubulin and has demonstrated activity
in untreated and pretreated SCLC.5–7
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Chemotherapy with etoposide, topotecan, and pacli-
taxel in combination may have superior efficacy because
these three drugs have different molecular targets. The fol-
lowing preclinical observations were considered in the design
of the treatment regimen: taxane exposure increases the
activity of drugs that target topoisomerase-I.8 Topotecan
targets topoisomerase-I and up-regulates topoisomerase-II.9
Etoposide targets topoisomerase-II. Topoisomerase-I and -II
inhibitors are synergistic when given sequentially and antag-
onistic when given concurrently.9,10 Topotecan followed by
etoposide is superior to the opposite sequence.10 Multiple
days of exposure to topoisomerase inhibitors seem necessary
for optimal effects.9 Interference with the topoisomerase-I
and -II activities leads to single- and double-strand breaks of
the DNA, and this may be particularly relevant in a rapidly
proliferating malignancy such as SCLC.
Topotecan and etoposide are available as oral formula-
tions and are bioavailable by this route of administration.11,12
Oral topotecan has a similar efficacy to intravenous topotecan
in the treatment of patients with relapsed SCLC, with less
grade 4 neutropenia and greater convenience of administra-
tion.13 Oral etoposide in combination with other chemother-
apeutic agents has been approved by the U.S. Food and Drug
Administration for the front-line therapy of SCLC. Therefore,
the regimen of intravenous paclitaxel, then oral topotecan,
and then oral etoposide is rational and clinically feasible.
Tolerable doses of these three drugs in combination have
been established by Rocha Lima et al.14 in a phase I study:
paclitaxel (110 mg/2, administered intravenously for 3 hours
on day 1), topotecan (1.5 mg/m2, administered orally on days
2 to 4), etoposide (160 mg/m2, administered orally on days 5
to 7), and filgrastim (administered subcutaneously starting
on day 8).
The Cancer and Leukemia Group B (CALGB) has prior
experience with the two-drug combination of paclitaxel and
topotecan. In a phase II study in extensive-stage SCLC,
intravenous paclitaxel (230 mg/m2 on day 1) and intravenous
topotecan (1 mg/m2 on days 1 to 5) produced excessive
toxicity,15 and the paclitaxel dose was attenuated to 175
mg/m2.16 In a subsequent phase II study in limited-stage
SCLC, two cycles of induction therapy with paclitaxel (175
mg/m2 on day 1) and topotecan (1 mg/m2 on days 1 to 5) with
filgrastim support were followed by three cycles of carbopla-
tin (area under the curve of 5 on day 1) and etoposide (100
mg/m2 on days 1 to 3) concurrent with thoracic irradiation.17
The thoracic radiotherapy was once daily to 70 Gy; this
proved to be safe and effective.17 The study reported here
integrated etoposide with paclitaxel and topotecan in the
induction therapy, which was followed by the same consol-
idation chemotherapy as in the prior study (carboplatin and
etoposide), concurrent with thoracic radiotherapy to 70 Gy.
The primary objective was to define the response rates to
induction and consolidation therapy in patients with limited-
stage SCLC. Secondary objectives were to describe the tox-
icity with induction and consolidation therapy and to docu-
ment overall and failure-free survival durations.
PATIENTS AND METHODS
Patient Eligibility
All patients had histologically or cytologically docu-
mented limited-stage SCLC. Limited stage was defined as
restricted to one hemithorax with regional lymph node me-
tastases, including hilar as well as ipsilateral and contralateral
mediastinal lymph nodes. Patients with supraclavicular
lymph node metastases (because of concern about the volume
of the radiation field) and patients with pleural effusions that
were visible on plain chest radiographs (whether cytologi-
cally positive or not) were not eligible. All patients had to
have measurable disease according to the Response Evalua-
tion Criteria in Solid Tumors (RECIST)18 by the National
Cancer Institute. Other eligibility criteria included age 18
years, Eastern Cooperative Oncology Group performance
status of 0 to 2, no prior chemotherapy for SCLC, no prior
thoracic radiotherapy, and no concurrent other malignancy.
Female patients who were pregnant or nursing were ex-
cluded. The required laboratory values at entry were absolute
neutrophil count (ANC) 1500/l; platelet count 100,000/
l; serum creatinine no greater than the upper limit of normal
(ULN); total bilirubin 1.5 mg/dl; and serum glutamic-
oxaloacetic transaminase (SGOT, aspartate aminotransferase
[AST]) less than twice the ULN. Each patient had to give
written informed consent after being informed of the diagno-
sis and of the research nature of the proposed treatment
program. The study had to be approved by the institutional
review board of each participating institution. Patients had to
be evaluated by a medical oncologist and a radiation oncol-
ogist before entry into the study, and the radiation oncologist
had to be identified at the time of registration with CALGB.
Treatment Plan
Patients received two cycles of induction chemotherapy
with intravenous paclitaxel, oral topotecan, oral etoposide,
and subcutaneous filgrastim support, at 21-day intervals (Fig-
FIGURE 1. Study schema. ANC, absolute neutrophil count; AUC, area under the concentration curve.
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ure 1). After restaging, all patients received three cycles of
consolidation therapy, with intravenous etoposide and carbo-
platin at 21-day intervals, concurrently with thoracic radia-
tion therapy to the postinduction tumor volume (Figure 1).
After a second restaging, those patients who had achieved a
complete response or good partial response received prophy-
lactic cranial irradiation.
Paclitaxel was infused intravenously for 3 hours after
the following premedications: dexamethasone (20 mg, ad-
ministered orally on the evening before and morning of
paclitaxel, or 20 mg, administered intravenously 30 minutes
before paclitaxel administration); diphenhydramine (50 mg,
administered intravenously 30 minutes before paclitaxel); and
cimetidine (300 mg), ranitidine (50 mg), or famotidine (20
mg), administered intravenously 30 minutes before pacli-
taxel. Antiemetic therapy was given at the discretion of the
treating physician. Topotecan was provided by SmithKline
Beecham in 0.25- and 1.0-mg capsules. All other drugs were
obtained from commercial sources. The carboplatin dose was
calculated using the Calvert formula19: carboplatin dose  5 
(creatinine clearance  25). The creatinine clearance was
estimated using the Cockcroft-Gault formula20; nevertheless,
the maximum allowable creatinine clearance was 150 ml/min
for males and 130 ml/min for females. Filgrastim was used
during the induction chemotherapy but not during the con-
solidation chemotherapy (Figure 1). Patients with rapidly
progressive disease after at least one cycle of therapy were
removed from protocol treatment.
On day 1 of subsequent cycles, treatment was held for
ANC 1500/l or platelets 100,000/l. Counts were re-
peated twice weekly, and therapy was reinstituted at 100%
when ANC was 1500/l and the platelet count was
100,000/l. For neutropenic fever (ANC 500/l and
temperature 100.5°F) requiring antibiotics, the doses of all
chemotherapy drugs were reduced by 25% for the next cycle.
If this occurred during induction chemotherapy, full doses of
etoposide and carboplatin were given for consolidation ther-
apy (cycles 3 through 5 of therapy). If neutropenic fever
recurred during consolidation therapy, the doses of etoposide
and carboplatin were reduced by 25%. If febrile neutropenia
requiring antibiotics occurred in cycles 3 or 4, additional dose
reductions of 25% for both etoposide and carboplatin were
instituted for all subsequent cycles of chemotherapy. For
grade 4 thrombocytopenia (platelets10,000/l), the dose of
all chemotherapy drugs was reduced by 25% from the pre-
vious dose in the next and in all subsequent cycles of
chemotherapy. There was no dose reescalation.
All patients without evidence of progressive disease
outside the planned radiation field (either regional or distant)
during induction chemotherapy began chest irradiation on
day 43, as in a prior CALGB study.17 The thoracic radiother-
apy planning was based on volumes from the restaging chest
computed tomography (CT) obtained after induction chemo-
therapy in all patients. Three-dimensional conformal radio-
therapy guidelines were incorporated, and treatment with
either two- or three-dimensional techniques was allowed. The
gross target volume (GTV) included residual lung tumor after
induction chemotherapy and involved lymph node regions
(both pre- and postchemotherapy). The initial clinical target
volume (CTV) included the GTV plus the ipsilateral hilar
lymph nodes and mediastinal lymph node stations 3, 4, and 7
(e.g., precarinal, lower paratracheal, and subcarinal). Medi-
astinal lymph node stations 5 and 6 (e.g., aortapulmonary
window and paraaortic) were included in the GTV for left-
sided tumors. After a tumor dose of 44 Gy, clinically unin-
volved mediastinal lymph nodes were excluded from the
CTV. The planning target volume included the CTV  1 cm.
Tissue heterogeneity corrections were not used.
Prophylactic cranial irradiation was scheduled to start 3
to 5 weeks after completion of chemotherapy, and concurrent
use of prophylactic cranial irradiation and chemotherapy was
not allowed. The dose and fractionation of prophylactic
cranial irradiation were at the discretion of the individual
investigator.
Clinical Evaluation
Before enrollment in the study and before each treat-
ment cycle, a comprehensive history and physical examina-
tion (including performance status) were performed, and
complete blood counts with differential and serum chemis-
tries were obtained. Blood counts were repeated twice weekly
while on filgrastim; otherwise, they were done weekly while
on treatment. Staging studies before enrollment, after induc-
tion chemotherapy, and after all therapy included chest x-ray,
CT, or magnetic resonance imaging of the chest and abdo-
men, bone scan, and CT or magnetic resonance imaging of
the brain. Bronchoscopies were performed as clinically indi-
cated. The RECIST criteria by the NCI were used.18 The NCI
Common Toxicity Criteria version 2.0 were in effect while
this trial was conducted.
Statistical Analyses
Patient registration and data collection were managed
by the CALGB statistical center. Data quality was ensured by
careful review of data by CALGB statistical center staff and
by the study chairman. Statistical analyses were performed by
CALGB statisticians. The goal of this trial was to determine
whether the complete chemoradiotherapy program had suffi-
cient merit to compare against “standard” treatment for lim-
ited-stage SCLC. The basis for making this decision was the
complete response rate. A single-stage study design was used
to differentiate between complete response rates of 50 and
70%. Specifically, the hypothesis tested was H0: p  0.5
versus H1: p  0.7, where p is the true proportion of patients
with complete response. The target accrual was 60 patients. If
36 or fewer patients had complete responses, we planned to
accept the null hypothesis and conclude that there was not
sufficient activity to merit further investigation in this setting.
Otherwise, we planned to conclude that the treatment regi-
men had sufficient activity to warrant further investigation.
The probability of erroneously concluding that the treatment
is active (p  0.7) when it is actually ineffective (p  0.5) is
less than 0.046 (i.e.,   0.046). The probability of errone-
ously concluding that the treatment is ineffective (p  0.5)
when the treatment is actually active (p  0.7) is less than
0.063 (i.e.,   0.063).
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Patients were followed for response and survival.
Kaplan-Meier curves were used to describe overall survival
and failure-free survival.21 Survival time was defined as the
time between registration and death. Failure-free survival was
the time from initiation of treatment until disease progression,
relapse, or death, whichever came first. The frequency of
toxicity occurrence was tabulated by type and grade.
RESULTS
Patient Characteristics
The study was activated in June 2001 and closed in
January 2003, and 65 patients were registered. One patient
never started treatment, and one patient was ineligible. The
characteristics of the 63 eligible and treated patients are
shown in Table 1. The patients were predominantly female
(57%), white (92%), had a performance status of 1 (52%),
and had experienced weight loss of less than 5% (70%).
Response
Response and survival were analyzed on an intent-to-
treat basis for all eligible patients assigned to the treatment
program, regardless of whether thoracic radiation therapy
was actually given. The reasons for not receiving thoracic
radiotherapy were (n  10) progressive disease (1), patient’s
death 44 days after registration (1), difference of opinions
regarding the feasibility of the radiation field between the
radiation oncologist at study entry and the radiation oncolo-
gist on day 43 (1), patient refusal (1), physician decision (2),
and toxicity of the induction chemotherapy (4). The response
to induction therapy and the response to overall therapy are
summarized in Table 2. Forty-one patients (65%) had objec-
tive responses to induction therapy, and 51 patients (81%)
had objective responses to the overall treatment program.
Nevertheless, the complete response of 43% (Table 2) was
less than the prospectively set target in the statistical design.
Twenty-eight patients (including the 27 patients with com-
plete response and one patient with near-complete response)
received prophylactic cranial irradiation.
Survival
The median follow-up time is 48 months. Forty-seven
patients have experienced treatment failure, and 46 patients
have died. The median failure-free and overall survival times
were 12 and 20 months, respectively (Table 3). Figures 2 and
3 depict the failure-free and overall survival curves. The
location of progression or relapse was captured in 26 patients;
Table 4 delineates where the progression or relapse occurred
with respect to the radiation field and the initial tumor volume
before chemotherapy. The radiotherapy treatment volumes
were defined after the two cycles of induction chemotherapy.
Because the complete plus partial response rate to induction
chemotherapy was 65%, the induction phase served to limit
the volume of the irradiated functioning lung in a significant
majority of all patients treated. Only 3 of 26 patients relapsed
or progressed outside the chosen radiation field but within the
prechemotherapy tumor volume (Table 4). The majority of
intrathoracic relapses or progressions were located outside
the prechemotherapy tumor volume.
Toxicity
All patients were evaluated for adverse events, except
for one patient who never received any protocol therapy.
Toxicity data were available for 61 of these 64 patients for
TABLE 2. Response to Therapy (n  63)
Induction
Therapy n (%)
Overall
Therapy n (%)
Complete response 6 (10%) 27 (43%)
Partial response 35 (56%) 24 (38%)
Stable disease 14 (22%) 6 (10%)
Progressive disease 1 (2%) 2 (3%)
Unevaluable 5 (8%) 2 (3%)
Missing data 1 (2%) 1 (2%)
Early deatha 1 (2%) 1 (2%)
Complete response
rate (95% CI)
10% (4–20%) 43% (30–56%)
Objective response
rate (95% CI)
65% (52–77%) 81% (69–90%)
CI, exact confidence interval.
a One patient died 44 days after registration and was not evaluated for response.
TABLE 3. Survival (n  63)
Survival
Median Time
in Months
(95% CI)
One-Year
Estimate
(95% CI)
Two-Year
Estimate
(95% CI)
Failure free 12 (9–15%) 46% (35–60%) 27% (18–41%)
Overall 20 (16–24%) 70% (59–82%) 35% (25–49%)
CI, confidence interval.
TABLE 1. Patient Characteristics (n  63)
Age
Median (range) 62 (38–78)
60 yr 38 (60%)
Sex
Female 36 (57%)
Male 27 (43%)
Race
White 58 (92%)
Black 3 (5%)
Other 1 (2%)
Unknown 1 (2%)
Performance status
0 27 (43%)
1 33 (52%)
2 3 (5%)
Weight loss
5% 44 (70%)
5–10% 10 (16%)
10% 3 (5%)
Unknown 6 (10%)
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induction therapy. Fifty patients were evaluable for toxicity
of the consolidation chemoradiotherapy. Table 5 summa-
rizes the rates of grade 3 and 4 adverse events by phase of
therapy. As expected, hematologic toxicity was the most
common adverse effect of therapy, with reversible neutro-
penia being the most frequent (80% for overall therapy)
type of toxicity. Nonhematologic toxicities were more
frequent during the consolidation chemoradiotherapy than
during the induction chemotherapy (Table 5). Dyspnea that
was possibly, probably, or definitely related to treatment
was infrequent (Table 5). Rates of acute toxicity, including
esophagitis, were consistent with other trials of concurrent
chemoradiotherapy. Late treatment-related toxicity in-
cluded a 5% rate of grade 3 dysphagia from radiation
therapy and a 5% rate of grade 3 radiation pneumonitis, but
no grade 4 events were recorded. Three grade 5 adverse
events were encountered (3 of 64 patients, or 4.7%).
During induction therapy, one patient died of febrile neu-
FIGURE 2. Failure-free survival.
FIGURE 3. Overall survival.
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tropenia and typhlitis, and a Jehovah’s Witness who de-
clined transfusion of packed red blood cells for anemia
died of cardiac ischemia. One patient died during consol-
idation chemoradiotherapy of febrile neutropenia.
DISCUSSION
This study was designed to prospectively test the hy-
pothesis that the rational addition of the topoisomerase-II
inhibitor, etoposide, to a two-drug regimen containing the
topoisomerase-I inhibitor, topotecan, along with paclitaxel,
would result in enhanced response rates and would ultimately
improve outcomes for patients with limited SCLC receiving
combined-modality therapy. The overall response rate of
65% (Table 2) in the current study was lower than the overall
response rate of 75% in the prior CALGB 39808 study17
assessing two-drug induction chemotherapy with topotecan
and paclitaxel. Both studies used the same consolidation
treatment program, which consisted of thoracic radiotherapy
to 70 Gy concurrent with three cycles of chemotherapy with
carboplatin and etoposide. Although this treatment program
had substantial activity and acceptable tolerability, the pri-
mary objective was not met, because the complete response
rate of 43% to the overall treatment program (Table 2) did not
meet our predetermined level of efficacy to merit further
investigation. The complete response rate may not have been
the optimal endpoint, because the radiological dilemma of
residual tumor versus radiation pneumonitis and fibrosis after
70 Gy made the application of RECIST18 problematic.
The overall treatment program resulted in an 81%
objective response rate in CALGB 30002 (Table 2) compared
with 92% in CALGB 39808. Both of these phase II trials
were of the same size (63 eligible patients) and had similar
patient demographics, except that in CALGB 39808 females
made up 46% of the population compared with 57% in
CALGB 30002, and females are known to have a better
outcome.2 The median survival of 20 months in CALGB
30002 did not differ significantly (p  0.05) from the 22-
month median survival in CALGB 39808. The apparent
plateau in the survival curves (Figures 1 and 2) after approx-
imately 20 months is encouraging.
Although there was substantial preclinical rationale to
justify exploring the combination of agents in this study,
employing a three-drug induction chemotherapy regimen was
not beneficial. In this respect, limited SCLC does not seem
different from extensive SCLC, where the three-drug regimen
of etoposide, cisplatin, and paclitaxel was not superior to
etoposide and cisplatin alone in a randomized phase III trial.22
In that study, any potential benefit of using a more intensive
chemotherapy regimen was offset by increased treatment-
related toxicity. Although the toxic effects of induction ther-
apy on the current trial do not seem increased compared with
the previous CALGB 39808 study, which used a two-drug
TABLE 4. Location of Progression/Relapse with Respect to
Radiation Field (n  26)
Relapse n (%)
Within the delivered/intended high-dose volume 7 (27%)
Within the delivered/intended low-dose volume 5 (19%)
Outside the field but within the prechemotherapy
tumor volume
3 (12%)
Outside the field and outside the prechemotherapy
tumor volume
15 (58%)
TABLE 5. Adverse Events of Grade 3 and 4 Severity during Induction, Consolidation, and Overall
Therapy with an Incidence of at Least 10%
Type of Toxicity
Inductiona Grade, n (%) Consolidationa Grade, n (%) Overalla Grade, n (%)
3 4 3 4 3 4
Hemoglobin 5 (8%) 1 (2%) 10 (20%) 2 (4%) 12 (19%) 3 (5%)
Leukocytes 5 (8%) 5 (8%) 12 (24%) 10 (20%) 14 (22%) 15 (23%)
Neutrophils 6 (10%) 17 (28%) 16 (32%) 26 (52%) 16 (25%) 35 (55%)
Lymphocytes 4 (7%) 0 (0%) 8 (16%) 1 (2%) 9 (14%) 1 (2%)
Platelets 3 (5%) 0 (0%) 27 (54%) 1 (2%) 29 (45%) 2 (3%)
Transfusion of pRBCs 7 (11%) 0 (0%) 10 (20%) 0 (0%) 15 (23%) 0 (0%)
Febrile neutropenia 9 (15%) 1 (2%) 6 (12%) 0 (0%) 15 (23%) 1 (2%)
Fatigue 3 (5%) 1 (2%) 7 (14%) 0 (0%) 13 (20%) 1 (2%)
Anorexia 3 (5%) 0 (0%) 6 (12%) 0 (0%) 9 (14%) 0 (0%)
Dehydration 3 (5%) 0 (0%) 7 (14%) 0 (0%) 10 (16%) 0 (0%)
Diarrhea 10 (16%) 0 (0%) 0 (0%) 0 (0%) 10 (16%) 0 (0%)
Dysphagia 1 (2%) 0 (0%) 16 (32%) 0 (0%) 19 (30%) 0 (0%)
Nausea 4 (7%) 0 (0%) 8 (16%) 0 (0%) 12 (19%) 0 (0%)
Vomiting 2 (3%) 0 (0%) 8 (16%) 0 (0%) 9 (14%) 0 (0%)
Dyspnea 2 (3%) 1 (2%) 2 (4%) 1 (2%) 6 (9%) 3 (5%)
pRBCs, packed red blood cells. a The total number of patients with available data equaled 61 for induction, 50 for consolidation, and
64 for overall therapy.
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induction regimen, fewer patients were able to proceed to
consolidation chemoradiotherapy after completion of two
cycles of induction chemotherapy: 53 of 63 patients in CALGB
30002 compared with 57 of 63 patients in CALGB 39808.
The results from CALGB 30002 confirm the prior
experience from CALGB 39808: once-daily thoracic radio-
therapy to 70 Gy can be delivered safely in the cooperative
group setting for patients with limited SCLC. The efficacy of
this radiotherapy regimen is difficult to discern because of
several confounding variables, including initiating thoracic
radiotherapy with the third cycle of chemotherapy, and the
use of a nonplatinum induction chemotherapy regimen. Al-
though recent meta-analyses have suggested that early
radiotherapy administration may be important when inten-
sive radiotherapy regimens are used,23,24 the optimal tim-
ing of radiotherapy remains controversial.25 Although
twice-daily radiotherapy to 45 Gy has been established as an
appropriate standard regimen on the basis of phase III data,26
the regimen has not been widely accepted in clinical practice.
The CALGB and the Radiation Therapy Oncology Group are
currently developing a three-arm phase III study for limited
SCLC, comparing (a) 70 Gy once-daily radiation, as in this
study; (b) twice-daily radiotherapy to 45 Gy; and (c) radio-
therapy to 61.2 Gy, with a concomitant boost technique.
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